Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Clinical pharmacogenomic testing of KRAS, BRAF and EGFRmutations by high resolution melting analysis and ultra-deep pyrosequencing

Figure 2

Sensitivity of the KRAS HRM assay. Mixtures of mutant (G12D heterozygous) and wild type genomic DNA samples reveal gradual curves. A) Adjusted melting curves (top) and differential plots (bottom) showing the presence of 50%, 25%, 10%, 5%, 2.5% and 0% mutant alleles. B) Melting peaks of mutant sample dilutions compared to the wild type control (left) and corresponding sequence traces (right). In the chromatograms, mutation peaks can be distinguished from the background because they are symmetrical and vertically aligned with the wild type peaks.

Back to article page